Identified as
  • v4.0.2
  • FAQ
  • SIGN UP / LOGIN
  • LOGIN

Bain Capital Life Sciences

New York
cb
Firm Location:New York • Massachusetts • New York, New York • Boston, Massachusetts • San Francisco Bay Area • New York City
Investor Firms That Co-Invest with Bain Capital Life Sciences
InterWestAbingworthGeneral AtlanticAgent CapitalRA CapitalForesite CapitalArtis Ventures (AV)SV Health InvestorsDeerfield ManagementARCH Venture PartnersRiverVestTriatomic CapitalSV AngelLongwood FundMRL Ventures FundAndera PartnersAccess BiotechnologyCofounders CapitalSection 32Red Tree Venture CapitalBain CapitalPolaris PartnersGV (Google Ventures)
Bain Capital Life Sciences Team
INVESTORSINTRO STRENGTHSWEET SPOT (RANGE)INVESTMENT LOCATIONSTOP INVESTMENT CATEGORIES
Photo of Brad Balter, Vice President at Bain Capital Life Sciences
Brad Balter
Bain Capital Life SciencesVice President
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists)
+3
Photo of Jonah Cashdan, Vice President at Bain Capital Life Sciences
Jonah Cashdan
Bain Capital Life SciencesVice President
n/a
$1.5M
($100K - $5.0M)
Investors in New York (NY)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Series B)
+3
Photo of Michael Cooney, Associate at Bain Capital Life Sciences
Michael Cooney
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists)
+3
Photo of Jennie Daisak, Associate at Bain Capital Life Sciences
Jennie Daisak
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in New York City
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in New York City (Other Lists), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+27
Photo of Nicholas Downing, Principal at Bain Capital Life Sciences
Nicholas Downing
Bain Capital Life SciencesPrincipal
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
DF
Drew Field
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in New York (NY)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in New York City (Other Lists), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+22
Photo of Dylan Goldstein, Associate at Bain Capital Life Sciences
Dylan Goldstein
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+27
Photo of Evan Greif, Associate at Bain Capital Life Sciences
Evan Greif
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
Photo of Andrew Hack, Managing Director at Bain Capital Life Sciences
Andrew Hack
Bain Capital Life SciencesManaging Director
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed)
+21
Photo of Adam Koppel, Managing Director at Bain Capital Life Sciences
Adam Koppel
Bain Capital Life SciencesManaging Director
n/a
$1.5M
($100K - $5.0M)
Investors in Boston / New England, Investors in Boston (MA), Investors in Massachusetts
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Boston / New England (Other Lists), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
Photo of Benjamin Lund, Principal at Bain Capital Life Sciences
Benjamin Lund
Bain Capital Life SciencesPrincipal
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
Photo of Ritika Mahal, Vice President at Bain Capital Life Sciences
Ritika Mahal
Bain Capital Life SciencesVice President
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
Photo of Tapan Maniar, Bain Capital Life Sciences
Tapan Maniar
Bain Capital Life Sciences
n/a
$1.5M
($100K - $5.0M)
Investors in SF Bay Area (CA)
Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Pharmaceuticals (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+22
Photo of Jeffrey Schwartz, Managing Director at Bain Capital Life Sciences
Jeffrey Schwartz
Bain Capital Life SciencesManaging Director
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Boston / New England (Other Lists), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
+16
Photo of Ricky Lijing Sun, Managing Director at Bain Capital Life Sciences
Ricky Lijing Sun
Bain Capital Life SciencesManaging Director
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Boston / New England (Other Lists)
+9
Photo of Harris Weber, Vice President at Bain Capital Life Sciences
Harris Weber
Bain Capital Life SciencesVice President
n/a
$1.5M
($100K - $5.0M)
Investors in New York
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A)
Photo of Julie Yang, Associate at Bain Capital Life Sciences
Julie Yang
Bain Capital Life SciencesAssociate
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists)
+3
Photo of Amir Zamani, Principal at Bain Capital Life Sciences
Amir Zamani
Bain Capital Life SciencesPrincipal
n/a
$1.5M
($100K - $5.0M)
Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists)
+3
Copyright © 2025NFX Capital. We invest.
FAQ Terms Privacy Disclosure
Log in for full access to the Signal investing network

Unlock your intro paths to 30,000+ Pre-Seed, Seed, and Serias A investors. It's free.

Or sign up or log in with email